Skip to main content
NCBI home page
British Journal of Experimental Pathology logoLink to British Journal of Experimental Pathology
. 1986 Feb;67(1):141–147.

Different effects of the polysaccharide levan on the oncogenicity of cells of two variants of Lewis lung carcinoma.

Y Stark, J Leibovici
PMCID: PMC2013074  PMID: 3947532

Abstract

A marked difference in sensitivity to the direct effect of the polysaccharide levan on tumour cells was observed between two variants of malignancy of Lewis lung carcinoma: cells of the more malignant variant (3LL-M) were much more sensitive to the drug than those of the less malignant tumour (3LL). A gradual decrease in tumorigenicity following preincubation with increasing levan concentrations was observed with both variants, but statistically significant inhibition was observed at lower levan concentrations with 3LL-M than with 3LL.

Full text

PDF
141

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cifone M. A., Fidler I. J. Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci U S A. 1981 Nov;78(11):6949–6952. doi: 10.1073/pnas.78.11.6949. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cooper C. S., Blair D. G., Oskarsson M. K., Tainsky M. A., Eader L. A., Vande Woude G. F. Characterization of human transforming genes from chemically transformed, teratocarcinoma, and pancreatic carcinoma cell lines. Cancer Res. 1984 Jan;44(1):1–10. [PubMed] [Google Scholar]
  3. Cummings R. D., Trowbridge I. S., Kornfeld S. A mouse lymphoma cell line resistant to the leukoagglutinating lectin from Phaseolus vulgaris is deficient in UDP-GlcNAc: alpha-D-mannoside beta 1,6 N-acetylglucosaminyltransferase. J Biol Chem. 1982 Nov 25;257(22):13421–13427. [PubMed] [Google Scholar]
  4. Dennis J. W., Kerbel R. S. Characterization of a deficiency in fucose metabolism in lectin-resistant variants of a murine tumor showing altered tumorigenic and metastatic capacities in vivo. Cancer Res. 1981 Jan;41(1):98–104. [PubMed] [Google Scholar]
  5. Gahmberg C. G., Andersson L. C. Surface glycoproteins of malignant human leukocytes. Biochim Biophys Acta. 1982 Apr 29;651(2-3):65–83. doi: 10.1016/0304-419x(82)90007-5. [DOI] [PubMed] [Google Scholar]
  6. Greco C., Calbresi F., Caputo M., Corsi A., Sacchi A., Zupi G. Adriamycin effect on the Lewis lung carcinoma. Comparison between the original line and its derivative subline. Eur J Cancer. 1980 Sep;16(9):1251–1255. doi: 10.1016/0014-2964(80)90185-1. [DOI] [PubMed] [Google Scholar]
  7. HESTRIN S., SHILO M., FEINGOLD D. S. Infection-promoting activity of levan and dextran as a function of degree of polymerization. Br J Exp Pathol. 1954 Apr;35(2):107–111. [PMC free article] [PubMed] [Google Scholar]
  8. Kimata K., Honma Y., Okayama M., Oguri K., Hozumi M., Suzuki S. Increased synthesis of hyaluronic acid by mouse mammary carcinoma cell variants with high metastatic potential. Cancer Res. 1983 Mar;43(3):1347–1354. [PubMed] [Google Scholar]
  9. Kodama Y., Seyama T., Kamiya K., Yokoro K. Establishment and immunologic characterization of 3-methylcholanthrene-induced sarcoma cell lines metastasizing widely in mice and exhibiting distinct and selective propensities for the mode of metastasis. J Natl Cancer Inst. 1982 Sep;69(3):595–605. [PubMed] [Google Scholar]
  10. Leibovici J., Borit A., Sandbank U., Wolman M. The role of macrophages and polymorphs in the levan-induced inhibition of Lewis lung carcinoma in C57BL mice. Br J Cancer. 1979 Oct;40(4):597–607. doi: 10.1038/bjc.1979.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Leibovici J., Sinai Y., Wolman M., Davidai G. Effects of high-molecular levan on the growth and spread of lymphoma in AKR mice. Cancer Res. 1975 Aug;35(8):1921–1925. [PubMed] [Google Scholar]
  12. Leibovici J. Spontaneous AKR lymphomas differ in their degree of malignancy and sensitivity to the polysaccharide levan. Experientia. 1983 Mar 15;39(3):326–327. doi: 10.1007/BF01955330. [DOI] [PubMed] [Google Scholar]
  13. Leibovici J., Stark Y. Direct antitumor effect of the polysaccharide levan in mice: effects of drug concentration and time and temperature of incubation. J Natl Cancer Inst. 1984 Jun;72(6):1417–1420. [PubMed] [Google Scholar]
  14. Leibovici J., Wolman M. Animal models for tumor progression (short review). Anticancer Res. 1984 May-Jun;4(3):165–168. [PubMed] [Google Scholar]
  15. Mantovani A. Effects on in vitro tumor growth of murine macrophages isolated from sarcoma lines differing in immunogenicity and metastasizing capacity. Int J Cancer. 1978 Dec;22(6):741–746. doi: 10.1002/ijc.2910220617. [DOI] [PubMed] [Google Scholar]
  16. Nowell P. C. The clonal evolution of tumor cell populations. Science. 1976 Oct 1;194(4260):23–28. doi: 10.1126/science.959840. [DOI] [PubMed] [Google Scholar]
  17. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sinai Y., Leibovici J., Wolman M. Effects of route and schedule of administration of high-molecular levan on the growth of AKR lymphoma. Cancer Res. 1976 May;36(5):1593–1597. [PubMed] [Google Scholar]
  19. Tropé C. Different sensitivity to cytostatic drugs of primary tumor and metastasis of the Lewis carcinoma. Neoplasma. 1975;22(2):171–180. [PubMed] [Google Scholar]

Articles from British journal of experimental pathology are provided here courtesy of Wiley

RESOURCES